A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies

Clinical Trial ID NCT01100944

Rank	Title	Journal	Year	PubWeight™‹?›
1	Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.	J Clin Oncol	1994	1.51
2	Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.	J Clin Oncol	2011	1.36
3	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2012	1.33
4	Thymoma: a focus on current therapeutic management.	J Thorac Oncol	2009	1.29
5	A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.	Clin Cancer Res	2014	0.98
6	Treatment of malignant thymoma.	Curr Opin Oncol	2005	0.95
7	Targeting Histone Deacetylases in Diseases: Where Are We?	Antioxid Redox Signal	2014	0.88
8	Targeted therapy for advanced thymic tumors.	J Thorac Oncol	2010	0.87
9	18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors.	Clin Cancer Res	2013	0.84
10	"Pseudocavitation" in thymic carcinoma during treatment with sunitinib.	J Thorac Oncol	2013	0.76
11	Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report.	Oncol Lett	2015	0.75